Millions of Americans with atrial fibrillation (AFib) also struggle with obesity, creating a complex clinical decision: can GLP-1 receptor agonists like semaglutide be used safely when you have an irregular heartbeat
Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
2 Data from the largest clinical trial of GLP-1s to date (the SELECT trial of nearly 18,000 participants) showed in November 2023 that Wegovy (Novo Nordisks GLP-1 for weight loss) reduced heart attacks, strokes and deaths due to cardiovascular disease and drove a 73% reduction in the progression toward diabetes versus the control group
Conclusions GLP-1 receptor agonists can be a pharmacological alternative to control excess weight and obesity, and may help in preventing cardiovascular disease, though some questions remain regarding the benefits of its use in our field
Dose adjustments are made based on symptoms and sensitivity under a clinicians guidance
Then request a batch-specific Certificate of Analysis from Body Pharm by quoting your intended batch number, and cross-check the HPLC purity and endotoxin values against your protocol requirements
.jpg)
